Not all that glitters is gold: off-target recombination in the somatostatin-IRES-Cre mouse line labels a subset of fast-spiking interneurons.

Front Neural Circuits

Department of Neurobiology and Anatomy and the Sensory Neuroscience Research Center, West Virginia University Morgantown, WV, USA.

Published: April 2014

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857604PMC
http://dx.doi.org/10.3389/fncir.2013.00195DOI Listing

Publication Analysis

Top Keywords

glitters gold
4
gold off-target
4
off-target recombination
4
recombination somatostatin-ires-cre
4
somatostatin-ires-cre mouse
4
mouse labels
4
labels subset
4
subset fast-spiking
4
fast-spiking interneurons
4
glitters
1

Similar Publications

Stibbard-Hawkes forcefully alerts us to the pitfall of false-negative reasoning in symbolic archaeology. We highlight the twin problem of false-positive reasoning in what we call the "false-symbol problem." False symbols are intuitively special entities that, owing to their non-utilitarian nature, invite symbolic interpretation.

View Article and Find Full Text PDF

Echocardiographic red flags in transthyretin amyloid cardiomyopathy: all that glitters is not gold.

Eur Heart J Imaging Methods Pract

July 2024

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Via Giustiniani, 2, Padua 35128, Italy.

View Article and Find Full Text PDF

Multidisciplinary team meeting (MDT) in cancer care: All that glitters is not gold.

Eur J Surg Oncol

October 2024

Division of Clinical Medicine, Faculty of Health, The Medical School, Sheffield, UK; Honorary Consultant Oncoplastic Breast Surgeon, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the low tumor doses achieved in non-prostate cancers treated with [Lu]Lu-PSMA radioligand, using a case of renal cell carcinoma as an example.
  • Despite high uptake of the imaging agent [Ga]Ga-PSMA-11, treatment with [Lu]Lu-PSMA-I&T resulted in low radiation doses to tumors (0.2-0.5 Gy) and no observable treatment effect.
  • The researchers suggest that the ineffective targeting may be due to PSMA receptors being located on new blood vessels rather than on tumor cells, leading to rapid washout; they propose using a radionuclide with a shorter half-life to improve treatment efficacy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!